Key Highlights

  • Spruce Biosciences introduced MPS3BStudy.com, a portal for caregivers and families of pediatric Sanfilippo Syndrome Type B patients.
  • The portal supports registration for the upcoming TA-ERT Expanded Access Program.
  • It also supports registration for the TrAnsform confirmatory trial.
  • Both programs are slated for initiation in the fourth quarter of 2026.

A Dedicated Resource for Families Ahead of Program Launches

Spruce Biosciences Inc. (NASDAQ:SPRB) introduced MPS3BStudy.com, a dedicated portal built for caregivers and families of pediatric patients with Sanfilippo Syndrome Type B, a rare and severe inherited metabolic disorder that causes progressive neurological decline in affected children. The portal is designed to give families direct access to information about the company's development programs and a way to register ahead of enrollment.

Launching a patient- and caregiver-facing information portal ahead of program initiation is a common step for rare pediatric disease developers, given the small and geographically dispersed patient populations typical of ultra-rare conditions, where early outreach can meaningfully affect enrollment timelines once a study opens.

Two Programs Set to Begin in Q4 2026

The portal specifically supports registration for two upcoming initiatives: the TA-ERT Expanded Access Program, which is designed to provide access to the company's enzyme replacement therapy candidate outside of a traditional randomized trial setting, and the TrAnsform confirmatory trial, a study intended to generate further confirmatory evidence of the therapy's benefit. Both are slated for initiation in the fourth quarter of 2026.

Why Expanded Access Matters in Ultra-Rare Disease

An Expanded Access Program allows eligible patients to receive an investigational therapy outside of the formal clinical trial structure, typically used in serious or life-threatening conditions with no adequate alternative treatment. For a progressive, ultra-rare pediatric condition like Sanfilippo Syndrome Type B, expanded access can offer earlier treatment Options for patients and families while the confirmatory trial continues to generate the data needed to support a potential future approval.

What is MPS3BStudy.com?

MPS3BStudy.com is a portal introduced by Spruce Biosciences (NASDAQ:SPRB) for caregivers and families of pediatric Sanfilippo Syndrome Type B patients to access information and register for upcoming programs.

What programs can families register for through the portal?

Families can register for the TA-ERT Expanded Access Program and the TrAnsform confirmatory trial.

When are these programs expected to begin?

Both the TA-ERT Expanded Access Program and the TrAnsform confirmatory trial are slated for initiation in the fourth quarter of 2026.